Genome-based therapeutics targeted drug discovery and development : workshop summary
(eBook)

Book Cover
Average Rating
Published
Washington, District of Columbia : National Academies Press, [2012].
Physical Desc
1 online resource (109 pages) : illustrations
Status

More Details

Format
eBook
Language
English
ISBN
9780309260251 (e-book)

Notes

Bibliography
Includes bibliographical references (pages 55-57).
Description
"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description.

Description

Loading Description...

Also in this Series

Checking series information...

More Like This

Loading more titles like this title...

Reading Recommendations & More

Reviews from GoodReads

Loading GoodReads Reviews.

Citations

APA Citation, 7th Edition (style guide)

Berger, A. C., & Olson, S. (2012). Genome-based therapeutics: targeted drug discovery and development : workshop summary . National Academies Press.

Chicago / Turabian - Author Date Citation, 17th Edition (style guide)

Berger, Adam C. and Steve Olson. 2012. Genome-based Therapeutics: Targeted Drug Discovery and Development : Workshop Summary. National Academies Press.

Chicago / Turabian - Humanities (Notes and Bibliography) Citation, 17th Edition (style guide)

Berger, Adam C. and Steve Olson. Genome-based Therapeutics: Targeted Drug Discovery and Development : Workshop Summary National Academies Press, 2012.

MLA Citation, 9th Edition (style guide)

Berger, Adam C.,, and Steve Olson. Genome-based Therapeutics: Targeted Drug Discovery and Development : Workshop Summary National Academies Press, 2012.

Note! Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy. Citation formats are based on standards as of August 2021.

Staff View

Grouped Work ID
da6f0bce-d4e5-06a8-78c0-1fdf743bb6a4-eng
Go To Grouped Work

Grouping Information

Grouped Work IDda6f0bce-d4e5-06a8-78c0-1fdf743bb6a4-eng
Full titlegenome based therapeutics targeted drug discovery and development workshop summary
Authoradam c berger and steve olson rapporteurs
Grouping Categorybook
Last Update2022-06-07 21:23:19PM
Last Indexed2024-04-13 05:32:29AM

Book Cover Information

Image Sourcesyndetics
First LoadedJul 7, 2022
Last UsedApr 14, 2024

Marc Record

First DetectedAug 09, 2021 01:10:13 PM
Last File Modification TimeNov 22, 2021 09:19:51 AM

MARC Record

LEADER05794nam a2200577 i 4500
001EBC3379240
003MiAaPQ
006m    E |      
007cr cnu||||||||
008130605t20122012dcua    ob    100 0 eng|d
020 |z 9780309260244
020 |z 0309260248
020 |z 9780309260213
020 |a 9780309260251 (e-book)
035 |a (Sirsi) EBC3379240
035 |a (Sirsi) EBC3379240
035 |a (MiAaPQ)EBC3379240
035 |a (Au-PeEL)EBL3379240
035 |a (CaPaEBR)ebr10863895
035 |a (OCoLC)817900348
040 |a MiAaPQ|b eng|c MiAaPQ|d MiAaPQ|e rda|e pn
043 |a n-us---
050 4|a RS420|b .G4 2012
0820 |a 615.1|2 23
24500|a Genome-based therapeutics |h [eBook]:|b targeted drug discovery and development : workshop summary /|c Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
24630|a Targeted drug discovery and development
264 1|a Washington, District of Columbia :|b National Academies Press,|c [2012]
264 4|c ©2012
300 |a 1 online resource (109 pages) :|b illustrations
336 |a text|2 rdacontent
337 |a computer|2 rdamedia
338 |a online resource|2 rdacarrier
504 |a Includes bibliographical references (pages 55-57).
5050 |a Introduction -- The current landscape -- Case studies: The development of Crizotinib for treatment of non-small-cell lung cancer; Use of genetics to inform drug development for the treatment of schizophrenia; A genetic approach to the treatment of cystic fibrosis -- Emerging technologies in drug development: Large-scale whole-genome sequencing; The value of clinical next-generation sequencing to drug developers; The uses of genomic information -- Evolving paradigms: Foundations and drug development: an example; Genomics and regulatory science; Pharmacy benefit management and pharmacogenomics; Repurposing of drugs -- Forging collaborative strategies for the development of personalized medicine: The need for collaboration; FDA initiatives; NCATS initiatives; Biospecimens and databases; Reducing health disparities; Patient and physican education; An emphasis on the science.
520 |a "The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description.
588 |a Description based on print version record.
650 0|a Drugs|z United States|x Design|v Congresses.
650 0|a Pharmaceutical technology|z United States|v Congresses.
650 0|a Pharmaceutical industry|z United States|v Congresses.
650 0|a Genomics|z United States|v Congresses.
655 4|a Electronic books.
7001 |a Berger, Adam C.,|e contributor.
7001 |a Olson, Steve,|d 1956-|e contributor.
7102 |a Institute of Medicine (U.S.).|b Roundtable on Translating Genomic-Based Research for Health,|e issuing body.
7102 |a Institute of Medicine (U.S.).|b Board on Health Sciences Policy,|e issuing body.
77608|i Print version:|t Genome-based therapeutics : targeted drug discovery and development : workshop summary.|d Washington, District of Columbia : National Academies Press, [2012]|h xx, 89 pages ; 23 cm.|z 9780309260213|w (OCoLC)ocn824457733|w (DLC) 2012554410
7972 |a ProQuest (Firm)
85640|u http://ebookcentral.proquest.com/lib/yavapai-ebooks/detail.action?docID=3379240|x Yavapai College|y Yavapai College users click here to access
85640|u http://ebookcentral.proquest.com/lib/prescottcollege-ebooks/detail.action?docID=3379240|x Prescott College|y Prescott College users click here to access
85640|u http://ebookcentral.proquest.com/lib/yln-ebooks/detail.action?docID=3379240|x Yavapai Library Network|y All other users click here to access
945 |a E-Book